The 4 analysts offering 12-month price forecasts for Carisma Therapeutics Inc have a median target of 10.00, with a high estimate of 11.00 and a low estimate of 7.00. The median estimate represents a +290.62% increase from the last price of 2.56.
The current consensus among 4 polled investment analysts is to Buy stock in Carisma Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.54
Reporting Date Apr 02
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.